Propanc Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 16:56 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-07-01 to 2021-09-30 | $46.6k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$486.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-07-01 to 2021-09-30 | $109.9k | us-gaap:InterestExpense |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$605.5k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2021-07-01 to 2021-09-30 | −$486.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-09-30 | $45.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $56.4k | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $62.2k | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $2.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $2.4m | us-gaap:Liabilities |
| Long-term debt | At period end2021-09-30 | $584.6k | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-09-30 | −$2.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-21-028221. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.